Compare Wahed FTSE USA Shariah ETF (HLAL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Sanofi SA — how do they compare? Wahed FTSE USA Shariah ETF trades at $71.28, while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA pays a 5.53% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| HLAL | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $52.34 |
52-Week Low | $54.05 | $41.33 |
Market Cap | — | $104.85B |
Enterprise Value | — | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $70.22, down 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock faces resistance at $71 and support at $70. Key financial ratios including P/E, P/S, and ROE are unavailable in the current dataset, limiting fundamental assessment. A small dividend of $0.02 is scheduled for June 2026.
The outlook remains cautious due to weak technical momentum and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to validate valuation. Primary risks include market volatility and lack of recent business updates. Analyst sentiment appears neutral to bearish given the technical configuration.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
